DOCSLIB.ORG

FULL SCIENTIFIC PROGRAM Full Scientific Program As of September 12, 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FULL SCIENTIFIC PROGRAM Full Scientific Program As of September 12, 2020 EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS MSVirtual2020.org #MSVirtual2020 FULL SCIENTIFIC PROGRAM Full Scientific Program as of September 12, 2020. For the most up-to-date program, please visit the MSVirtual2020 Full Online Program. Table of Contents Friday, September 11, 2020 .......................................................................................................................... 4 Plenary Session 1 ...................................................................................................................................... 4 Plenary Session 1: Welcome and Paty Lecture ..................................................................................... 4 Parallel Sessions 1-4 .................................................................................................................................. 4 PS01 - Strategies for disease modification............................................................................................ 4 PS02 - Innate immunity in MS pathology and repair ............................................................................ 5 PS03 - Biomarkers ................................................................................................................................. 6 PS04 - Impact of the environment and lifestyle and MS risk and clinical course ................................. 7 Parallel Sessions 5-8 .................................................................................................................................. 8 PS05 - Pharmacological management of progressive MS .................................................................... 8 PS06 - Lymphocyte subsets in MS ......................................................................................................... 9 PS07 - Radiological advances I (NAIMS/MAGNIMS) ........................................................................... 10 PS08 - Epigenetics and genetic factors ............................................................................................... 11 Saturday, September 12, 2020 ................................................................................................................... 12 Parallel Session 9-12………………………………………………………………………………………………………………………….13 PS09 - Personalized approaches to MS ............................................................................................... 12 PS10 - Gut-CNS axis and the microbiome in MS ................................................................................. 13 PS11 - Radiological advances II ........................................................................................................... 14 PS12 - Sex-related factors in pathogenesis and management ........................................................... 15 European Charcot Foundation Symposium, Nurse’s Session 1, Young Investigator Session 1 .............. 16 CS01 - European Charcot Foundation Symposium ............................................................................. 16 NS01 - Advanced nursing activities ..................................................................................................... 17 YI01 - Young Investigators 1 ................................................................................................................ 17 Parallel Session 13-16 ............................................................................................................................. 18 PS13 - Innovations in symptomatic and rehabilitative therapy .......................................................... 18 PS14 - The impact of MS on neurons and glia .................................................................................... 18 PS15 - Visual outcome measures in MS (IMSVISUAL) ......................................................................... 19 PS16 - Machine learning approaches .................................................................................................. 20 Sunday, September 13 ................................................................................................................................ 22 Hot Topics 1-4 ......................................................................................................................................... 22 HT01 - Strategies to promote remyelination ...................................................................................... 22 HT02 - Aging and multiple sclerosis .................................................................................................... 22 HT03 - Developments in pediatric MS ................................................................................................ 22 HT04 - Grey matter pathology ............................................................................................................ 22 Hot Topics 5-7 ......................................................................................................................................... 23 HT05 - Lymphoid follicles and meningeal involvement in MS ............................................................ 23 HT06 - Global perspectives on neuromyelitis optica spectrum disorders .......................................... 23 HT07 - MOG mediated disease ........................................................................................................... 24 Nurse’s Session 2 and Young Investigator Session 2 .............................................................................. 24 NS02 - Unique contributions of MS nursing ....................................................................................... 24 YI02 - Young Investigators 2 ................................................................................................................ 24 Free Communications 1-4 ....................................................................................................................... 27 Free Communications 1 ...................................................................................................................... 27 FC02 - Free Communications 2 ........................................................................................................... 28 FC03 - Free Communications 3 ........................................................................................................... 29 FC04 - Free Communications 4 ........................................................................................................... 30 Plenary Session 2 .................................................................................................................................... 32 Plenary Session 2 - ACTRIMS-ECTRIMS Lecture and Closing .............................................................. 32 Saturday, September 26 ............................................................................................................................. 32 Late Breaking News ................................................................................................................................. 32 LB01 - Late Breaking News .................................................................................................................. 32 Special Session: COVID-19 ...................................................................................................................... 34 SS02 - COVID-19 .................................................................................................................................. 34 On-Demand Program .................................................................................................................................. 36 Burning Debates ...................................................................................................................................... 36 BD01 - DMTs prevent/slow down cognitive impairment in MS ........................................................... 36 BD02 - DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity ................................................................................................................................................. 36 BD03 - Microglia are protective in MS ................................................................................................. 36 Meet the Experts .................................................................................................................................... 37 MTE01 - CNS in disorders in children .................................................................................................. 37 MTE02 - Neuro-ophthalmology of MS ................................................................................................ 37 MTE03 - B-cell-directed therapy in MS ................................................................................................ 37 MTE04 - Choosing the right MS disease therapy for individual patients ............................................. 37 MTE05 - Immune disorders of the CNS other than MS ....................................................................... 37 Teaching Courses .................................................................................................................................... 37 TC01 - Ultra-high-field (7T) MRI in MS (NAIMS) .................................................................................. 37 TC02 - Neurofilaments and other biomarkers of CNS disease............................................................. 37 TC03 - NMO
Load more

Recommended publications
  • Planungsstand Und Zeitliche Realisierbarkeit
    Tesla-Kooperationsraum Karte 2 Wohnbauflächenpotenziale Planungsstand und zeitliche Realisierbarkeit Bernau bei Berlin Reichenow- Möglin Werneuchen Prötzel Panketal Letschin Märkische Bleyen- Höhe Neuhardenberg Zechin Genschmar Pankow Ahrensfelde Oberbarnim Altlandsberg Gusow-Platkow Strausberg Buckow Golzow (Märkische Schweiz) Küstriner Vorland Lichten- Seelow berg Waldsievers- Neuenhagen Petershagen Garzau-Garzin dorf bei Berlin /Eggersdorf Marzahn- Alt Tucheband Berlin Hellersdorf Fredersdorf- Vierlinden Vogelsdorf Rehfelde Müncheberg Hoppe- Reitwein garten Lindendorf Schöneiche Rüdersdorf Podelzig bei Berlin bei Berlin Lietzen Fichtenhöhe Wolters- Neukölln dorf Falkenhagen Lebus Treptow- (Mark) Grünheide (Mark) Steinhöfel Zeschdorf Köpenick Erkner !! Treplin Schönefeld Gosen- Eich- Neu Zittau Briesen walde Fürstenwalde/Spree (Mark) Schulzen- Berken- dorf brück Zeuthen Langewahl Jacobsdorf Spreenhagen Wildau Rauen Frankfurt Königs (Oder) Wusterhausen Rangs- Reichen- dorf walde Mittenwalde Heidesee Bad Saarow Brieskow- Rietz-Neuendorf Müllrose Finkenheerd Diensdorf- Groß Bestensee Storkow (Mark) Radlow Lindow Wiesenau Ragow-Merz Wendisch Mixdorf Siehdichum Zossen Rietz Beeskow Groß Köris Schwerin Münchehofe Grunow- Schlaubetal Teupitz Tauche Dammendorf Märkisch Buchholz Friedland Unter- Halbe spree- wald Märkische Heide Neuzelle Baruth/Mark Krausnick- Groß Wasserburg Jamlitz Rietzneuendorf- Schlepzig Schwielochsee Staakow 0 10 20km Brandenburger Kommunen Potenzialflächen Rücklauf in ha Potenzialflächen nach Planungsstand 300 Raumbeobachtung
    [Show full text]
  • A Short History of the Soviet/Russian Western Group of Forces in Germany 1945-1994
    Copyright by Elliott Carson Nowacky 2012 The Thesis Committee for Elliott Carson Nowacky Certifies that this is the approved version of the following thesis: From Occupation to Withdrawal: A Short History of the Soviet/Russian Western Group of Forces in Germany 1945-1994 APPROVED BY SUPERVISING COMMITTEE: Supervisor: Thomas J. Garza Bella B. Jordan From Occupation to Withdrawal: A Short History of the Soviet/Russian Western Group of Forces in Germany 1945-1994 by Elliott Carson Nowacky, B.A History Thesis Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Master of Arts The University of Texas at Austin August 2012 Dedication To my late parents Ed and Catherine. Acknowledgements This thesis would not have been possible without the help of many people. I would like to thank Professor Thomas Garza and Dr. Bella Bychkova-Jordan for their guidance, constructive criticism and ever present enthusiasm during the writing process. My appreciation also goes to Andriy, Elena and Yuri at the NovaMova Language Institute in Kiev. Andriy, who is also one of the people I interviewed for this project, went above the call of duty in arranging an additional interview with another ZGV veteran in L’viv for me during my short time in Ukraine. Yuri helped me slog through Michael Boltunov’s Gorkaya Doroga Domoi and Elena assisted in preparing my interview questions in Russian. Kudos are also in order for Jay K. and Brandon P, my former “battle buddies” here at UT; Thanks for helping a middle-aged graduate student remain sane.
    [Show full text]
  • Official Journal L 338 Volume 35 of the European Communities 23 November 1992
    ISSN 0378 - 6978 Official Journal L 338 Volume 35 of the European Communities 23 November 1992 English edition Legislation Contents I Acts whose publication is obligatory II Acts whose publication is not obligatory Council Council Directive 92 /92/ EEC of 9 November 1992 amending Directive 86/ 465 / EEC concerning the Community list of less-favoured farming areas within the meaning of Directive 75 / 268 / EEC (Federal Republic of Germany) 'New Lander* 1 Council Directive 92 /93 / EEC of 9 November 1992 amending Directive 75 /275 / EEC concerning the Community list of less-favoured farming areas within the meaning of Directive 75 / 268/ EEC (Netherlands) 40 Council Directive 92 / 94/ EEC of 9 November 1992 amending Directive 75 / 273 /EEC concerning the Community list of less-favoured farming areas within the meaning of Directive 75 / 268/ EEC (Italy) 42 2 Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period . The titles of all other Acts are printed in bold type and preceded by an asterisk. 23 . 11 . 92 Official Journal of the European Communities No L 338 / 1 II (Acts whose publication is not obligatory) COUNCIL COUNCIL DIRECTIVE 92/92/ EEC of 9 November 1992 amending Directive 86 /465 / EEC concerning the Community list of less-favoured farming areas within the meaning of Directive 75 /268 / EEC (Federal Republic of Germany ) 'New Lander' THE COUNCIL OF THE EUROPEAN COMMUNITIES , Commission of the areas considered eligible for inclusion
    [Show full text]
  • 211855Orig1s000
    &(17(5)25'58*(9$/8$7,21$1' 5(6($5&+ APPLICATION NUMBER: 2ULJV 6800$5<5(9,(: Summary Memorandum for Regulato1y Action Summary Memorandum for Regulatory Action Date October 11, 2019 Paul Lee, MD, PhD From Nick Kozauer, MD Subject Summary Memorandum for Regulatory Action NDA/BLA # and Supplement# NDA 211855 under 505(b)(2)1 Applicant Alkermes Date of Submission December 13, 2018 PDUFA Goal Date October 13, 2019 Proprietary Name Vun1erity Established or Proper Name Diroximel fumarate Dosage Form(s) 231 mg delayed release capsules Applicant Proposed VUMERITY is indicated for the treatment of adult patients Indication(s)/Population(s) with relapsing forms of multiple sclerosis The starting dose for VUMERITY is 231 mg twice a day Applicant Proposed Dosing orally. After 7 days, the dose should be increased to 462 Regimen(s) mg (two 231 mg capsules) twice daily orally. Recommendation on Tentative Approval Regulatory Action VUMERITY is indicated for the treatment of adult patients Recommended with relapsing forms of multiple sclerosis (MS), to include Indication(s)/Population(s) (if clinically isolated syndrome, relapsing-remitting disease, applicable) and active secondary progressive d isease, in adults Recommended Dosing Same as proposed Recimen(s) (if applicable) 1The referenced dmg for this 505(b)(2) application is Tecfidera (NDA 204063) Reference ID: 4504909 Summary Memorandum for Regulatory Action 1. Benefit-Risk Assessment The application provides an adequate bridge to Tecfidera, the referenced product for this 505(b)(2) application. Therefore, the previous findings of safety and effectiveness for Tecfidera also apply to Vumerity. 2. Background The applicant seeks approval of Vumerity (diroximel fumarate) using the 505(b)(2) regulatory pathway for monomethyl fumarate (MMF), relying on the previous findings of safety and effectiveness for Tecfidera (dimethyl fumarate [DMF]).
    [Show full text]
  • Oral MS Disease-Modifying Therapies C21142-A
    Drug and Biologic Coverage Criteria Effective Date: 05/01/2019 Last P&T Approval/Version: 07/28/2021 Next Review Due By: 08/2022 Policy Number: C21142-A Oral MS Disease-Modifying Therapies PRODUCTS AFFECTED Mayzent (siponimod), Aubagio (teriflunomide), Gilenya (fingolimod), Mavenclad (cladribine), Tecfidera (dimethyl fumarate), Vumerity (diroximel fumarate), Bafiertam (monomethyl fumarate),dimethyl fumarate, Zeposia (ozanimod), Ponvory (ponesimod) COVERAGE POLICY Coverage for services, procedures, medical devices, and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines Documentation Requirements: Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A.
    [Show full text]
  • Multiple Sclerosis
    bmchp.org | 888-566-0008 wellsense.org | 877-957-1300 Pharmacy Policy Multiple Sclerosis Policy Number: 9.212 Version Number: 2.0 Version Effective Date: 6/1/2021 Product Applicability All Plan+ Products Well Sense Health Plan Boston Medical Center HealthNet Plan New Hampshire Medicaid MassHealth ACO NH Health Protection Program MassHealth MCO Qualified Health Plans/ConnectorCare/Employer Choice Direct Senior Care Options Note: Disclaimer and audit information is located at the end of this document. Prior Authorization Policy Products Affected: Aubagio (teriflunomide) Kesimpta (ofatumumab) Avonex pen (interferon beta-1a) Mayzent (siponimod) Betaseron (interferon beta-1b) Plegridy (peginterferon beta-1a) Dalfampridine ER Rebif (interferon beta-1a) Dimethyl fumarate Tecfidera (dimethyl fumarate) (NF) Gilenya (fingolimod) Vumerity (diroximel fumarate) Glatiramer Zeposia (ozanimod) The Plan may authorize coverage of the above product(s) for members meeting the following criteria: Avonex, Betaseron, glatiramer, Plegridy, Rebif Initial Criteria 1. Member is 18 years of age and older; AND NF = non-formulary + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan. Multiple Scerlosis 2. Diagnosis of relapsing multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease; AND 3. Prescribed by or in consultation with a neurologist; AND 4. Will not be used in combination with another MS disease modifying agent; AND 5. Will not be given concurrently with live vaccines; AND 6.
    [Show full text]
  • Der Neue Goethebogen - Seit Ende Mai´03 Für Den Verkehr Wieder Freigegeben AM ZEUTHENER SEE - 2 - 11.Jahrgang
    11. Jahrgang Mittwoch, den 23.07.2003 Nummer 7 Woche 30 Aus dem Inhalt * Aus der Gemeindevertretersitzung am 2. Juli 2003 Seite 2 * Von der Scheune bis zum Schloss Seite 7 * Kommentar des Monats Seite 3 * Literaturfreunde Seite 8 * Der Bürgermeister gratuliert .... Seite 4 * Ortschronisten melden sich zu Wort Seite 9 * Männerchor weilte im polnischen Malomice Seite 5 * Bündnis 90/ Die Grünen laden zum Gespräch Seite 9 * Die Gemeinde- &Kinderbibliothek Zeuthen informiert Seite 6 * Seniorenbeirat informiert Seite 10 * Preisträger der Zeuthener Woche 2003 Seite 7 * Der BVBB informiert... Seite 10 * Cadet-Weltmeisterschaft in Nieuwpoort in Belgien Seite 7 * Ihre Apotheke - Nähe ist unersetzbar! Seite 14 Der neue Goethebogen - seit Ende Mai´03 für den Verkehr wieder freigegeben AM ZEUTHENER SEE - 2 - 11.Jahrgang Aus der Gemeindevertretersitzung am 2. Juli 2003 ERLASS der 1. NACHTRAGSSATZUNG Belange statt. Nunmehr wurde der städtebauliche Rahmenplan als zur Haushaltssatzung der Gemeinde Zeuthen Selbstbindung der Gemeindevertretung beschlossen. Er bildet einen für das Haushaltsjahr 2003 Handlungsrahmen für die Verwaltung u. a. zur Beantragung von Fördermitteln. Im Laufe des Haushaltsjahres ergaben sich Veränderungen in den Haushaltsansätzen, die einen Nachtrag zur Haushaltssatzung für das Haushaltsjahr 2003 erforderten. Erlass einer Widmungsverfügung für die Verkehrsfläche - Folgende Veränderungen sind zu nennen: Parkplatz Bahnstraße 1. Reduzierung der Einnahmen aus Gewerbesteuern durch Rückzah- Gemäß § 6 des Brandenburgischen Straßengesetzes vom 11.06.1992 in lung von Vorauszahlungen aus Vorjahren und der damit verbunde- der derzeit geltenden Fassung erhält folgende in der Gemeinde Zeuthen, nen Reduzierung der laufenden Vorauszahlung von rd. 180.000 €, Gemarkung Zeuthen, Flur 13, Flurstück 46, davon 3.600m2 gelegene 2. Reduzierung der Schlüsselzuweisungen das Landes Brandenburg Verkehrsfläche die Eigenschaft einer öffentlichen Verkehrsfläche und gemäß Festsetzungsbescheid vom April 2003 um 360.000 €, wird der Allgemeinheit für den öffentliche Nutzung zur Verfügung 3.
    [Show full text]
  • Prior Authorization Multiple Sclerosis – Ponvory™ (Ponesimod Tablets)
    Cigna National Formulary Coverage Policy Prior Authorization Multiple Sclerosis – Ponvory™ (ponesimod tablets) Table of Contents Product Identifier(s) National Formulary Medical Necessity ................ 1 79750 Conditions Not Covered....................................... 2 Background .......................................................... 2 References .......................................................... 2 Revision History ................................................... 2 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]
  • 5948 6 March 2020 Freedom of Information Request I Am Writing In
    Trust Headquarters East Surrey Hospital Canada Avenue Redhill RH1 5RH Tel: 01737 768511 www.surreyandsussex.nhs.uk Our ref: 5948 6 March 2020 Freedom of information request I am writing in response to your request for information which has been handled under the Freedom of Information Act 2000 (FOIA). Could you please provide us with the numbers of patients in relation to the questions mentioned below, for a period of last 12 months: We do not record the number of patients who have attended the trust who have a diagnosis on MS 1. In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment? We only record the number of patients who have attended the trust who have a diagnosis but we are unable to tell if they were diagnosed for the first time within this admission. 2. Of these MS patients, how many have been diagnosed with relapsing (RRMS), primary progressive (PPMS) or secondary progressive (SPMS) MS; See above If you do not code your MS patients in this way, do you have plans to do this? RRMS PPMS SPMS Not known 3. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months. Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs: See question 5 below. Aubagio (teriflunomide) Avonex (interferon beta-1a) Betaferon (interferon beta-1b) Brabio (glatiramer acetate) Copaxone (glatiramer acetate) Extavia (beta interferon-1b) Gilenya (fingolimod) Lemtrada (alemtuzumab) Mavenclad (cladribine) Mayzent (siponimod) Ocrevus (ocrelizumab) Plegridy (peginterferon beta-1a) Rebif (beta interferon-1a) Tecfidera (dimethyl fumarate) Tysabri (natalizumab) Vumerity (diroximel fumarate) Zinbryta (daclizumab) Ampyra (fampyra) Ozanimod 4.
    [Show full text]
  • Timeline of Progress in MS Research
    Timeline of Progress in MS Research This timeline highlights a selection of major landmarks in research into multiple sclerosis and the launch of programs to propel this research forward. These are only a few of thousands of advances in basic and clinical research that have laid the foundation for the rapid progress we’re seeing today. 1421 First documented case of MS; St. Lidwina of Schiedam 1860-70 First studies of myelin and glial cells in brain tissue 1868 First correlation of MS clinical symptoms with central nervous system pathology; disease named "Sclerose en plaques" by Jean Martin Charcot 1869 First attempts to treat MS with gold chloride, zinc, sulfate, silver nitrate, strychnine and electrical stimulation (by Charcot) 1928 Discovery that myelin is produced by oligodendrocyte glial cells 1933 Acute experimental allergic encephalomyelitis (EAE) developed as model for MS 1936 Discovery that lymphocytes are involved in immune function 1943 First detailed description of the composition of myelin 1946 National MS Society USA Launched 1947 First research grant to Elvin A. Kabat, MD 1950 National Institute of Neurological Diseases founded at National Institutes of Health through the work of the Society 1950 Society funds first major survey of MS in the U.S. and Canada 1954 First Fellowship programs to train MS Scientists offered 1965 Society-convened panel of experts develops precise criteria for diagnosing MS 1969 Society co-funds research of steroid ACTH, which becomes the first drug shown to speed recovery from MS relapses 1974
    [Show full text]
  • Complete Report
    INTERNATIONAL CO N G RESS OF JURISTS WEST BERLIN 1952 Complete Report Discourses Pro tocols Printed by Rudolf Ofto, 63, Lutzowsfrcsse, Berlin W 35, Germony « The first greatINTERNATIONAL CONGRESS OF JURISTSfor the protection of Right against Systematic Injustice was recently held in West Berlin with the cooperation of Delegates from 43 countries, amongst whom were 31 Ministers and Statesmen, 32 Professors, 35 Presidents, Judges and Counsel in High Courts of Justice. The names of these Delegates warrant that the resolutions were passed by the Congress unprejudiced by political questions of the day and after scrupulous examination of the documentary material and the hearing of witnesses. The publication of this report is being done not for propaganda purposes, but with the object of spreading the truth in order to maintain and defend Law against an im­ minent danger not yet sufficiently understood by the Free World. Published by the International Commission- of Jurists 47, Buitenhof, The Hague, Netherlands Berlin■ Offices: 5, Lindenthaler Allee, Berlin-Zehlendorf-West, Germany i 1/0t f a k e tin likexhp to inform you that the Collection of Documents often referred to in this report as hearing the title “Injustice as a System” is in the original entitled “Injustice the Regime C ontents Page Page Part One: The Development of Public Law in Latvia, by M. C a k ste............................................................ 26 Preparation Legal Development in Estonia, , and Plenary Meetings of Congress by H. Mark ............................! ...................... ................ 27 FOURTH D A Y ................................................................... 30 IDEA AND PREPARATION ....................................... 1 Discussion and adoption of the Resolution of the Committee FIRST PLENARY MEETING......................................
    [Show full text]
  • Rettungsdienstbereichsplan Landkreis Dahme-Spreewald
    Rettungsdienstbereichsplan Landkreis Dahme-Spreewald Stand: 01. Januar 2020 Inhaltsverzeichnis 1. Einwohnerzahlen der Städte, Ämter und amtsfreien Gemeinden ........................... 3 1.1 Rettungsdienstbereich Landkreis Dahme-Spreewald ......................................... 3 1.2 Übersicht der Gemeinden des Landkreises Dahme-Spreewald ......................... 3 2 Rettungswachenstandorte und Vorhaltung ............................................................. 5 3 Personelle Vorhaltung – Besetzung der Fahrzeuge ............................................... 8 4 Notarztstandorte im Rettungsdienstbereich ............................................................ 9 4.1 Notarztstandort Königs Wusterhausen ............................................................... 9 4.2 Notarztstandort Lübben ...................................................................................... 9 4.3 Notarztstandort Luckau ....................................................................................... 9 4.4 Notarztstandort Teupitz ....................................................................................... 9 4.5 Notarztstandort Schönefeld ................................................................................ 9 5 Regionalleitstelle des Rettungsdienstes ................................................................. 9 6 Leistungserbringer der im Landkreis befindlichen Rettungswachen ..................... 10 7 Leitendes Personal im Rettungsdienstbereich ..................................................... 10 7.1
    [Show full text]